Mirum Pharmaceuticals, Inc. Common Stock (MIRM)
Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for rare and orphan diseases, particularly those affecting the liver. The company aims to address unmet medical needs through innovative and targeted treatments.
Company News
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 3 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.6, a high estimate of $72.00, and a low estimate of $35.00. This current average represents a 1.29% decrease from the previous average price target of $53.29. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ed Arce HC Wainwright & Co. Maintains Buy $58.00 - Dae Gon Ha Stifel Announces Buy $48.00 - Ed Arce HC Wainwright & Co. Maintains Buy $58.00 $58.00 Mani Foroohar Leerink Partners Lowers Outperform $43.00 $44.00 Jonathan Wolleben JMP Securities Raises Outperform $72.00 $69.00 Ed Arce HC Wainwright & Co. Raises Buy $58.00 $45.00 Josh Schimmer Cantor Fitzgerald Raises Overweight $40.00 $35.00 Ed Arce HC Wainwright & Co. Lowers Buy $45.00 $58.00 Jonathan Wolleben JMP Securities Raises Market Outperform $69.00 $64.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $35.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...Full story available on Benzinga.com
Bubbles in the AI sector are deflating, while rising interest rates are impacting the commercial real estate sector. Read more to see my thoughts.
A mixed trial could hurt a kidney drug's chances of full approval.